Yinhua CSI Innovative Drugs Industry ETF(159992) Rises 3.26%, with Share Count Growing by 2 Billion Units Over the Past 3 Months

NewTimeSpace (newtimespace.com) News, – As of 13:59 on August 4, 2026, Yinhua Innovative Drug ETF (159992) rose 3.26%, with its latest price at RMB 0.86.

In terms of liquidity, Yinhua Innovative Drug ETF recorded a turnover rate of 6.15% during the session, with trading volume reaching RMB 1.064 billion. Over a longer period, as of August 3, the ETF’s average daily turnover over the past month was RMB 1.348 billion, ranking first among comparable funds.

In terms of scale, the ETF’s scale grew by RMB 1.406 billion over the past six months, achieving significant growth and ranking 3rd among 7 comparable funds in new scale additions. (Data source: Wind)

In terms of units, the ETF’s share count grew by 2.000 billion units over the past 3 months, achieving significant growth and ranking 3rd among 7 comparable funds in new share additions. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. Yinhua Innovative Drug ETF recorded a net margin buying of RMB 23.8612 million in the previous trading day, with its latest margin balance standing at RMB 682 million. (Data source: Wind)

As of August 3, the net value of Yinhua Innovative Drug ETF had risen 0.69% over the past 6 months. In terms of return capability, as of August 3, 2026, since its inception, the ETF achieved a highest single‑month return of 22.79%, a longest consecutive winning streak of 4 months with a cumulative gain of 53.27%, and an average monthly return of 6.39% during up months. As of August 3, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 4.26%.

In terms of drawdown, as of August 3, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.18%. The recovery period after drawdown was 28 days, the fastest recovery among comparable funds.

On fees, Yinhua Innovative Drug ETF charges a management fee of 0.50% and a custody fee of 0.05%.

On tracking accuracy, as of August 3, 2026, the ETF’s 1‑month tracking error was 0.032%, representing a relatively high tracking precision among comparable funds.

From a valuation perspective, the CSI Innovative Drug Industry Index, which the ETF tracks, has a latest price‑to‑earnings (PE‑TTM) ratio of only 47.41x, which is at the 15.63rd percentile over the past year, meaning the valuation is lower than for more than 84.38% of the time over the past year, placing it at a historical low.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The index selects no more than 50 representative listed company securities whose primary business involves innovative drug research and development as index samples, reflecting the overall performance of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.